Voyager Therapeutics
Market cap $94.6M 62.2M shares (10-Q, Oct 30, 2026) × $1.52 close Nov 17, 2026
Most recent annual filing: 2026-03-09
- VY7523 interim4Q 2026VY7523 interim, 4Q 2026, major
- VY1706 trial start4Q 2026VY1706 trial start, 4Q 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
VY7523
frataxin gene therapy
NBIB-'223glucosylceramidase beta 1 gene therapy
TDP-43 targeting small molecule
selective small molecules
Technology platforms
TRACER
Tropism Redirection of AAV by Cell-type-specific Expression of RNA — RNA-based AAV capsid discovery platform enabling rapid discovery of capsids with robust BBB penetration and enhanced CNS tropism in multiple species including NHPs; used to generate novel capsids for intravenously delivered AAV gene therapies targeting neurological diseases including Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, SMA, and Huntington's disease.
Targets: ALPL, ApoE4, ApoE2
Voyager NeuroShuttle
Non-viral delivery platform leveraging novel receptor-binding molecules (initially ALPL receptor) to transport multiple modalities of neurotherapeutics across the blood-brain barrier; early discovery stage targeting undisclosed neurological disease; demonstrated sustained brain expression over three weeks in murine proof-of-concept studies.
Targets: ALPL, TfR
Capital (as filed)
- Cash
- $48.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $58.4M Sep 30, 2026
- Long-term investments
- $25.3M Sep 30, 2026
- Operating cash flow
- −$19.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $132M cash, runway Q2 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (10)
- 2026-11-06 UPDATE: Voyager Therapeutics (VYGR) - The Quiet Slip in the Q3 Print 🔒 Paid
- 2026-10-22 UPDATE: Voyager Therapeutics (VYGR) - The Scientist Hands Over the Keys 🔒 Paid
- 2026-08-07 UPDATE: Voyager Therapeutics (VYGR) - The Catalysts Slide Into Q4 🔒 Paid
- 2026-06-10 UPDATE: Voyager Therapeutics (VYGR) - The War-Chest Vote Passes 🔒 Paid
- 2026-06-02 UPDATE: Voyager Therapeutics (VYGR) - The IND Lands
- 2026-05-16 UPDATE: Voyager Therapeutics (VYGR) - EcoR1 Walks 🔒 Paid
- 2026-05-14 UPDATE: Voyager Therapeutics (VYGR) - The AAV Liver Ghost Got Quieter 🔒 Paid
- 2026-05-08 UPDATE: Voyager Therapeutics (VYGR) - The Q1 Print Answers Two Open Questions 🔒 Paid
- 2026-04-27 UPDATE: Voyager Therapeutics (VYGR) - The Second C-Suite Exit and the 240M-Share Tell 🔒 Paid
- 2026-03-17 Voyager Therapeutics (VYGR) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (10 calls)
Every verdict Biotech Distilled has published on Voyager Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-17 Watch Voyager Therapeutics (VYGR) - Scientific Deep Dive for Lead and Pipeline Products Voyager is a high-value delivery platform with compelling NHP data but binary H2 2026 clinical risk; smart money should let Biogen absorb the primary biological risk before deploying capital.
- 2026-04-27 Watch UPDATE: Voyager Therapeutics (VYGR) - The Second C-Suite Exit and the 240M-Share Tell Two C-suite exits in 70 days plus a proxy request to double authorized shares deepens the bear case; the proxy waiting game is the right call with dilution risk now actively widening.
- 2026-05-08 Watch UPDATE: Voyager Therapeutics (VYGR) - The Q1 Print Answers Two Open Questions Q1 GLP tox confirmed on schedule and Type C FDA meeting disclosed are positive process signals, but the ATM is now live and dilution risk is real; the proxy waiting game continues with a slightly cleaner edge.
- 2026-05-14 Watch UPDATE: Voyager Therapeutics (VYGR) - The AAV Liver Ghost Got Quieter Clean 3-month NHP tox at top dose and reproduced tau knockdown efficacy de-risk the AAV liver ghost, and the ALPL receptor reveal compounds platform optionality, but Biogen readout and FIH dosing still own the directional decision.
- 2026-05-16 Watch UPDATE: Voyager Therapeutics (VYGR) - EcoR1 Walks EcoR1's full exit from a 6.6% anchor position two days after the ASGCT preclinical win narrows the institutional shoulder and walks back the gentle bull lean to neutral.
- 2026-06-02 Watch UPDATE: Voyager Therapeutics (VYGR) - The IND Lands FDA cleared the VY1706 IND on schedule with no clinical hold and a dose ceiling preserving the 4x NHP safety margin, but the Biogen readout and FIH dosing still own the directional decision.
- 2026-06-10 Watch UPDATE: Voyager Therapeutics (VYGR) - The War-Chest Vote Passes 240M authorized shares approved 99.4% makes dilution authority structural, stock down 12.4% since IND clearance, and a 29.5% Geraghty withhold signals governance concern; the right register remains watch from the sidelines.
- 2026-08-07 Watch UPDATE: Voyager Therapeutics (VYGR) - The Catalysts Slide Into Q4 Both Alzheimer's catalysts pushed to Q4 2026, VY1706 first human safety data slipped to early 2027, ATM tapped into weakness at ~$3.61, and cash at $148.8M; the proxy waiting game got longer.
- 2026-10-22 Watch UPDATE: Voyager Therapeutics (VYGR) - The Scientist Hands Over the Keys CEO and acting CMO exits after safety readout with CMO and CFO seats still unfilled, stock down 35.5% since August and trading near cash, making the proxy waiting game better played after the readouts than before.
- 2026-11-06 Watch UPDATE: Voyager Therapeutics (VYGR) - The Quiet Slip in the Q3 Print VY1706 dosing slipped from Q4 2026 to 'next few months,' a September layoff appeared only in the 10-Q, ATM selling at lower prices, and stock trades ~$25M below cash; proxy waiting game still better played after the data.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (8 quotes from 5 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“VY7523 (anti-tau antibody): The last patient visit is complete, and Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).”
matched to VY7523 · interim data
-
-
-
“We anticipate announcing this update in the first quarter of 2027, subject to the progress and timing of the enrollment and dosing of patients.”
matched to VY1706 · trial initiation -
“We expect to announce initial tau PET imaging efficacy data in the fourth quarter of 2026.”
matched to VY7523 · interim data
-
-
-
“VY7523 (anti-tau antibody): Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).”
matched to VY7523 · interim data
-
-
-
“Dosing is expected to begin in the fourth quarter of 2026.”
matched to VY1706 · trial initiation -
“Enrollment in this MAD clinical trial was completed in the fourth quarter of 2025, and we expect initial tau PET imaging efficacy data in the fourth quarter of 2026.”
matched to VY7523 · interim data
-
-
-
“Dosing is expected to begin in the fourth quarter of 2026.”
matched to VY1706 · trial initiation -
“Enrollment in this MAD clinical trial was completed in the fourth quarter of 2025, and we expect initial tau PET imaging efficacy data in the fourth quarter of 2026.”
matched to VY7523 · interim data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 5, 2026ReleaseVoyager Reports Third Quarter 2026 Financial and Operating Results→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: acquisition / disposition · EX-99.1→ BD updateVoyager's Q3 print lands with $132.1M cash, a fully confirmed Q4 VY7523 PET readout, and VY1706 dosing on a "pending enrollment" clock — while the ATM is being worked below $3.50 and the stock now trades at a ~19% discount to cash.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 27, 2026ReleaseVoyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
- Oct 21, 2026ReleaseVoyager Announces CEO Succession Plan, Appoints Robin Swartz President→ BD update
- Oct 21, 20268-KCurrent report: officer / director change→ BD update
- Sep 1, 2026ReleaseVoyager to Present at Upcoming Investor Conferences
- Aug 6, 2026ReleaseVoyager Reports Second Quarter 2026 Financial and Operating Results
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → VYGR pipeline
- Jul 13, 2026ReleaseVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026BD extracted 1 program update from this document → VYGR pipeline
- Jul 13, 20268-KCurrent report: other events
- Jun 29, 2026ReleaseVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
- Jun 11, 2026ReleaseVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
- Jun 10, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- Jun 1, 2026ReleaseVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
- Jun 1, 20268-KCurrent report: other events
- May 13, 2026ReleaseVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
- May 7, 2026ReleaseVoyager Reports First Quarter 2026 Financial and Operating Results
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 21, 20268-KCurrent report: officer / director change
- Mar 9, 20268-KCurrent report: results of operations · EX-99.1
- Mar 9, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 31, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 28, 2026ARSAnnual report to shareholders
- Apr 10, 2026PRE 14APRE 14A
- Mar 27, 2026SCHEDULE 13G/A13G amendment